Abstract 6042
Background
Leadership is nursing is widely discussed and recognised as an important element in nursing services and indeed in health service development. Nurse leaders are in a prime position to facilitate and drive change within the healthcare setting. Nurse leaders can be role models within the workforce and integral in guiding and motivating teams to meet organisational goals. Whilst it often feels change within the clinical environment, occurs at a rapid rate or too frequently, resulting in a degree of change fatigue amongst nursing colleagues. Organisational change is often in response to advancements in medical knowledge, workforce demands or in this case, infrastructure change in response to increased demand upon a service. The authors work in a busy cancer centre, which delivers day case chemotherapy to approximately 130 patients a day. Delays resulting from patients attending day care in blocks of time resulted in bottle necks, meaning many faced long waits for their chemotherapy. A new scheduling system was implemented to focus booking patients based on chair availability and thus staggered more consistently across the day. The objective of the change was to improve patients’ attendance on our chemotherapy day unit, to prevent lengthy delays and streamline the process of delivering chemotherapy. The focus of this review, is how nursing leadership was instrumental in delivering change and how nurses are optimally positioned to drive change and manage projects in the healthcare setting.
Methods
A project was undertaken to implement a new electronic system for scheduling chemotherapy for a busy chemo day service. The project was led by oncology nurses within the service.
Results
The project outcome to implement a new electronic scheduling system was achieved in a timely manner. The project drivers did encounter some reticence, when colleagues faced new ways of working. Open and constant dialogue was maintained to ensure all stakeholders were fully apprised of the rationale for the change, the timescale and outcomes.
Conclusions
The importance of steady, intelligent leadership from nurses cannot be overestimated. Solidarity amongst nursing colleagues and allied health professionals is essential to optimise organisational efficacy and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract